Genmab AS (NAS:GMAB)
$ 23.12 -0.02 (-0.09%) Market Cap: 14.68 Bil Enterprise Value: 12.55 Bil PE Ratio: 19.09 PB Ratio: 3.24 GF Score: 88/100

Q1 2020 Genmab A/S Earnings Call Transcript

May 06, 2020 / 04:00PM GMT
Release Date Price: $25.53 (+2.08%)
Operator;Jan G. J.

Ladies and gentlemen, thank you for standing by, and welcome to Genmab's First Quarter Report 2020 Conference Call. (Operator Instructions)

During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results might differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under an obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law.

Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

I must advise you that this conference is being recorded today.

And now I would like to hand the conference over to one of your speakers today, Jan van de Winkel. Please go ahead.

(technical Difficulties]

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot